Parkinson’s disease (PD) is the second most common progressive neurodegenerative disorder after Alzheimer’s disease. Pathophysiologically, it is characterized by intracytoplasmic aggregates of α-synuclein protein in the Lewy body and loss of dopaminergic neurons from substantia nigra pars compacta and striatum regions of the brain. Although the exact mechanism of neurodegeneration is not fully elucidated, it has been reported that environmental toxins such as MPTP, rotenone, paraquat, and MPP+ induce oxidative stress, which is one of the causative factors for it. To date, there is no complete cure. However, the indispensable role of oxidative stress in mediating PD indicates that antioxidant therapy could be a possible therapeutic strategy against the disease. The deficiency of vitamins has been extensively co-related to PD. Dietary supplementation of vitamins with antioxidant, anti-inflammatory, anti-apoptotic, and free radical scavenging properties could be the potential neuroprotective therapeutic strategy. This review summarizes the studies that evaluated the role of vitamins (A, B, C, D, E, and K) in PD. It will guide future studies in understanding the potential therapeutic role of vitamins in disease pathophysiology and may provide a framework for designing treatment strategies against the disease.
Background: Alzheimer’s Disease (AD), the most common form of dementia, is a growing global health concern with unmet clinical therapeutics. AD can be attributed to amyloid beta aggregation and tau hyperphosphorylation‐induced oxidative stress and neurodegeneration in the brain. Previous studies have implicated a hyper‐activated Hippo signaling pathway with neuronal loss in neurodegenerative disorders, including AD. However, it is still unknown if suppressing the Hippo pathway can rescue neuronal death in AD.Method: In this study, we investigated the cognitive impairment ameliorative effect of the novel Hippo signaling inhibitor, Xmu‐mp‐1, in a rat model of AD. Adult male Wistar rats were stereotaxically injected with a well‐known AD inducer Streptozotocin (STZ), to mimic AD‐like features. A pharmacological antagonist of Hippo signaling component MST1 called Xmu‐mp‐1 was administered intraperitoneally at a dose of 0.5mg/kg body weight for 14 days. Then the effect of Xmu‐mp‐1 on cognitive impairment was assessed using the Morris water maze test and novel object recognition test. Further, we did biochemical and histopathological studies to explore the effect of Xmu‐mp‐1 on several AD‐associated pathophysiological changes, including oxidative stress, tau hyperphosphorylation, and neurodegeneration.Result: Xmu‐mp‐1 significantly improved the cognitive impairment of the AD rats in the Morris water maze test and the novel object recognition test (n = 7). Biochemical analysis of the brain hippocampal and cortical tissues revealed that Xmu‐mp‐1 also ameliorated the AD‐associated oxidative stress burden as the levels of anti‐oxidants (SOD, Catalase, GSH) significantly increased and the levels of oxidative stress biomarkers (protein carbonyl and lipid peroxidation) significantly reduced after Xmu‐mp‐1 treatment in the AD rats (n = 6). Moreover, the level of tau phosphorylation, a prime characteristic of AD, was also reduced following Xmu‐mp‐1 treatment (n = 3). Finally, neuronal death was also found to be rescued after Xmu‐mp‐1 treatment in AD rats (n = 3).Conclusion: Xmu‐mp‐1 exhibits a neuroprotective role against AD as it improves the cognitive impairment induced by STZ. Further mechanistic investigations into the neuroprotective role of Xmu‐mp‐1 revealed that Xmu‐mp‐1 provides protection from oxidative stress, tau hyperphosphorylation, and aberrant neurodegeneration under an AD background. Future studies can explore the therapeutic potential of Hippo signaling inhibition against AD in more detail.
15 September 2021 in Indian Journal of Forensic and Community Medicine
Role of state and medical officials in case of sexual assault by an insane person: A case report - IJFCM- Print ISSN No: - 2394-6768 Online ISSN No:- 2394-6776 Article DOI No:- 10.18231/j.ijfcm.2021.040, Indian Journal of Forensic and Community Medicine-Indian J Forensic Community Med